Now let me write the final consolidated review.

## Summary

This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that internally generates "lesion proposals" via a Grade-Activated Lesion Proposal (GALP) module (using CAMs from auxiliary classifiers) and fuses cross-view information through a Lesion Expert Guided Regional Fusion (LGRF) module with mixture-of-experts routing. The central goal is to match the accuracy of methods that require costly external lesion/vessel annotations without needing those annotations. Experiments on two multi-view DR datasets (MFIDDR, DRTiD) show competitive results, with the lesion-free variant surpassing all end-to-end baselines and approaching or matching several externally-informed methods.

## Strengths

- **Practically motivated and clearly scoped problem.** The paper identifies a genuine bottleneck: methods using external lesion/vessel annotations achieve higher accuracy but impose annotation burden and system brittleness. The goal of reducing this dependency without sacrificing accuracy is concretely worthwhile, and the paper states this clearly.
- **Competitive experimental scope.** The method is evaluated on two multi-view DR datasets against 10+ baselines spanning both end-to-end and externally-informed approaches. Reporting both a lesion-free version and a version that can incorporate external annotations gives a complete picture of the framework's capabilities.
- **Quantitative results are competitive.** On MFIDDR, the lesion-free variant achieves 83.9% accuracy, surpassing all end-to-end baselines and several externally-informed ones. On DRTiD, it achieves 76.0% accuracy, the best reported on this benchmark. These are non-trivial results that suggest the overall approach is on the right track.

## Weaknesses

### Major

- **No validation that "self-derived lesion proposals" correspond to lesions.** The paper's core narrative is that GALP's top-K CAM-selected regions are lesion proposals that act as surrogates for external annotations. However, the paper provides zero evidence for this claim: no example fundus images overlaid with GEM heatmaps, no comparisons showing whether selected proposals overlap with ground-truth lesion segmentations (which are available for MFIDDR), no quantitative measures of proposal quality (e.g., lesion recall/precision), and no failure case analysis. The ablation (Table 4) removes GALP entirely but does not compare CAM-based selection against random patch selection or uniform grid proposals — comparisons that would isolate whether the "lesion-specific" nature of selection matters or whether the benefit comes from token sparsification or the auxiliary supervision alone. Contribution (2) also claims "superior robustness and interpretability" without evaluating either. This is a significant evidential gap for a method whose name is built around "Lesion Proposal."

- **No uncertainty estimates or statistical significance.** All results (Tables 1–4, Fig. 3) are reported as single-point estimates with no confidence intervals, standard deviations, or significance tests. Many claimed improvements are tiny: on DRTiD the gap over CrossFIT is 0.4% in accuracy (76.0 vs 75.6); on MFIDDR, the gap between Ours w/o lesion (83.9%) and WGLIN (84.2%) is 0.3% in the *opposite* direction. Without variance estimates, the reader cannot assess whether these differences are reproducible or simply noise. This is especially important because the MoE routing mechanism introduces stochasticity that could inflate variance.

### Minor

- **DRTiD AUC claims are overstated.** The paper states the method "achieves the highest overall accuracy, outperforming all existing methods" (accurate for accuracy) and "consistently achieves competitive or superior results across different grades." However, the AUC breakdown shows mixed results: Grade 0 AUC (94.6 vs 94.7 for CrossFIT) and Grade 2 AUC (85.3 vs 85.8 for CrossFIT) are slightly below CrossFIT, an externally-informed baseline. The text overstates the uniformity of the advantage.

- **Insufficient description of the "with lesion" variant.** The variant that achieves the paper's best results (84.6% accuracy on MFIDDR) is described in one sentence: "lesion segments are fused with the original images via Spatially-Adaptive Denormalization (SPADE)." Where SPADE is applied in the pipeline, how lesion maps are preprocessed, and whether the SPADE block is trained end-to-end are not specified.

- **LGRF cyclic fusion choice is unremarked.** The LGRF module fuses each view with only one adjacent view in a cyclic chain (view i with view i+1). For the 4-view MFIDDR dataset, this means view 1 never directly receives information from views 3 or 4. The paper does not justify this design choice or discuss alternatives (e.g., pairwise fusion, shared fusion center).

- **Ablation conflates the auxiliary loss and the proposal selection.** The w/o GALP ablation removes both the auxiliary classification loss and the top-K proposal selection simultaneously. A drop in performance does not reveal which factor matters. The paper would benefit from isolating these factors: (a) auxiliary loss only without proposal selection, (b) random patch selection instead of CAM-based selection, (c) all tokens with auxiliary loss.

### Trivial

- **Notation inconsistency in Eq. (3).** The weight vector is introduced as $\mathbf{w}_{s_n}^i \in \mathbb{R}^{C_{s_n}}$ (superscript i for view index) but used as $\mathbf{w}_{s_n, c}^{(s_n)}$ (superscript changes to s_n) without explanation.

## Nice-to-Haves

- Code release would aid reproducibility given the pipeline's complexity.
- An explanation for the missing specificity values ("-") for several baselines in Table 2.
- A discussion of limitations: failure modes, when self-derived proposals might fail (e.g., early-stage DR with sparse lesions), and dataset biases.

## Removed Points

These points from the Harsh Critic input were filtered out as not meeting the review guidelines:
- *"Three stages framing is a bit tidy"* — removed as a non-substantive presentation criticism.
- *Criticism about missing appendix content* — the PDF parser strips appendix sections from all papers; they exist in the original submission.
- *"No code release mentioned" framed as a weakness* — moved to Nice-to-Haves, as it is a reproducibility suggestion, not a flaw in the scientific content.

## Novel Insights

None beyond the paper's own contributions.

## Suggestions

1. **Directly validate the lesion proposals.** Show GEM heatmaps overlaid on fundus images, quantitatively evaluate proposal quality against available lesion segmentation masks on MFIDDR (report lesion recall/precision of selected proposals), and compare CAM-based selection against random patch selection at the same retention ratio.
2. **Add an ablation isolating the auxiliary loss from proposal selection.** Train a version with the auxiliary classifiers and loss but using all tokens (no top-K selection) for LGRF fusion.
3. **Report all main results as mean ± std over at least 3–5 runs.** This is essential when performance margins are <1%.
4. **Justify the cyclic fusion design** or discuss alternatives.
5. **Expand the description of the SPADE-based "with lesion" variant** so it can be properly understood.
6. **Tone down overclaiming** about "superior robustness and interpretability," neither of which is evaluated.

## Score and Decision

**Calibration anchor papers retrieved across all rounds:**

| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| nSDOkm0SKo.md (financial NNs) | 1.00 | R1 | Topic mismatch, strong reject anchor |
| 5lUdTogEL3.md (person ReID) | 1.00 | R1 | Topic mismatch, strong reject anchor |
| EjIKerYk1O.md (aircraft estimation) | 2.33 | R1 | Topic mismatch, reject anchor |
| SNNdmfqWFu.md (multi-view spectral) | 3.40 | R1 | Different domain, lower quality |
| ZBH4fqQwJQ.md (multi-view diffusion) | 4.75 | R1 | Different task, comparable methodological depth |
| NJxCpMt0sf.md (medical MoE) | 5.75 | R2 | **Most comparable:** medical imaging with MoE, similar weaknesses (no significance tests), similar contribution level |
| Naiy1jf8UA.md (medical segmentation) | 6.00 | R2 | Medical imaging, incremental improvement concerns |
| i2r7LDjba3.md (ECHO generation) | 6.80 | R2 | Medical imaging, stronger validation than current paper |
| QG31By6S6w.md (lesion segmentation) | 6.25 | R2 | Medical imaging, stronger core-claim validation |
| M3kBtqpys5.md (multi-view classification) | 6.25 | R2 | Multi-view classification, similar domain |
| RqJ0px8osW.md (image fusion) | 6.80 | R2 | Different domain, stronger empirical work |

**Round 1 bracket:** 5–7 (narrowed from the full range based on comparable medical imaging papers scoring 5.75–6.80)

**Round 2 narrowing:** Compared with the most relevant anchors — the paper is stronger than the 5.75 medical MoE paper (broader experimental scope, clearer motivation) but notably weaker than papers at 6.25+ (which validate their core claims more thoroughly). The presence of a significant but fixable evidential gap (no validation of lesion proposals) and the absence of uncertainty estimates in a medical paper anchors the score at the lower end of the 6-range.

**Final score rationale:** The paper tackles a well-motivated problem, proposes a sensible pipeline-level solution, and achieves competitive quantitative results. However, its central narrative — that internally-generated "lesion proposals" drive the improvement — is entirely unvalidated, and the lack of statistical significance testing makes the tiny margins uninterpretable. These gaps are substantive but fixable.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>